Contact Us

Yes. GSK3β rescue experiments are well-established for kinase research: • Construct design: use a codon-modified GSK3B sequence with a small C-terminal tag (FLAG, HA). GSK3β has N-terminal regulatory S9 phospho-site, central kinase domain, and C-terminal region — preserve all elements. • Kinase-dead rescue: K85R or D200A mutations abolish catalytic activity and serve as the standard specificity control. • Constitutively active rescue: S9A mutation removes the autoinhibitory PI3K-AKT-mediated phosphorylation site, generating constitutively active GSK3β — invaluable for separating PI3K-AKT-regulated from constitutively active GSK3β functions. • Functional readout: rescue should restore β-catenin phosphorylation, tau phosphorylation, and lithium sensitivity. HAP1-specific considerations: • Diploidization: HAP1 cells gradually diploidize during extended culture — confirm ploidy by flow cytometry at the time of phenotypic assay. • Integration site sensitivity: position effects on transgene expression are more pronounced in near-haploid backgrounds; generating multiple independent rescue clones is strongly recommended. • Transduction efficiency: HAP1 transduces with lentivirus at moderate efficiency — increase MOI compared to standard immortalized lines.

The choice depends on whether you are studying GABBR1 (GABA-B receptor 1)'s role as the ligand-binding subunit of the GABA-B receptor or its functions in inhibitory neurotransmission. The Knockout line is the standard tool for asking whether GABBR1 is required for GABA-B signaling — GABBR1 partners obligately with GABBR2 to form the functional heterodimeric GABA-B receptor, a Gi-coupled class C GPCR; GABBR1 contains the GABA-binding pocket while GABBR2 contains the G protein-coupling interface. Overexpression is useful for studying GABBR1 in heterologous expression contexts. Important consideration: GABBR1 is principally functional in CNS neurons — HAP1 is not the physiological context for canonical GABA-B receptor function. The EDITGENE GABBR1 Knockout in HAP1 is most useful for biochemistry, heterologous expression, and as a clean genetic background for structure-function studies. Rescue with wild-type GABBR1 enables structure-function studies. The knockout is a critical specificity control for baclofen (GABA-B agonist, FDA-approved for spasticity), arbaclofen (R-baclofen), and emerging GABA-B-targeted therapeutics.

Yes. GABBR1 rescue experiments require attention to obligate heterodimer formation: • Construct design: use a codon-modified GABBR1 sequence with a small intracellular tag (FLAG, HA). GABBR1 has extracellular Venus flytrap GABA-binding domain, sushi domains, and seven-transmembrane region — preserve all elements. • Surface localization validation: confirm plasma membrane localization — GABBR1 alone is retained in ER without GABBR2 partnership. • GABBR2 partnership: rescue interpretation considers GABBR2 expression — heterodimer formation is required for surface expression and function. • Functional readout: rescue (with GABBR2 expression) should restore GABA-induced cAMP suppression and GIRK channel activation. HAP1-specific considerations: • Diploidization: HAP1 cells gradually diploidize during extended culture — confirm ploidy by flow cytometry at the time of phenotypic assay. • Integration site sensitivity: position effects on transgene expression are more pronounced in near-haploid backgrounds; generating multiple independent rescue clones is strongly recommended. • Transduction efficiency: HAP1 transduces with lentivirus at moderate efficiency — increase MOI compared to standard immortalized lines.

The choice depends on whether you are studying F2RL1 (PAR2, protease-activated receptor 2)'s role as a tryptase/trypsin/elastase-activated GPCR or modeling its functions in inflammation, itch, and gastrointestinal disease. The Knockout line is the standard tool for asking whether PAR2 is required for these processes — F2RL1/PAR2 is one of four PAR family GPCRs (PAR1/F2R, PAR2/F2RL1, PAR3/F2RL2, PAR4/F2RL3) activated by proteolytic cleavage of the extracellular N-terminus, exposing a tethered ligand; PAR2 is activated by mast cell tryptase, trypsin, neutrophil elastase, and other serine proteases, with established roles in inflammation, pain, itch, and GI biology. Overexpression is useful for studying PAR2 in heterologous expression contexts. For gastrointestinal/esophageal research, the EDITGENE F2RL1 Knockout in OE33 is highly relevant — OE33 is an esophageal adenocarcinoma cell line, and PAR2 has been characterized in Barrett's esophagus and esophageal adenocarcinoma biology with implications for GERD-related disease. Rescue with wild-type or cleavage-resistant (Arg36Ala — the tryptase/trypsin cleavage site) PAR2 enables structure-function studies. The knockout is a critical specificity control for PAR2 antagonists (PZ-235, GB88) in asthma, IBD, and itch drug development.

Yes. PAR2 rescue experiments require attention to protease cleavage activation: • Construct design: use a codon-modified F2RL1 sequence with a small intracellular C-terminal tag (FLAG, HA). PAR2 is a seven-transmembrane GPCR — preserve N-terminal extracellular tail with cleavage sites. • Cleavage-site-mutant rescue: R36A mutation in the tryptase/trypsin cleavage site (S37LIGRL... tethered ligand) abolishes protease activation; this generates a PAR2 that responds only to exogenous activating peptides (PAR2-AP), enabling separation of biased activation modes. • Surface localization validation: confirm plasma membrane localization before functional assays. • Functional readout: rescue should restore protease-induced PAR2 activation measured by Ca²⁺ mobilization and ERK phosphorylation. OE33-specific considerations: • OE33 is a human esophageal adenocarcinoma cell line derived from Barrett's esophagus-associated adenocarcinoma — a relevant model for esophageal adenocarcinoma biology, which has a rising incidence in Western countries. • Lentiviral transduction is supported with moderate efficiency. • OE33's esophageal adenocarcinoma origin makes it relevant for studying gastrointestinal Barrett's progression and adenocarcinoma biology.

The choice depends on whether you are studying F2R (PAR1, protease-activated receptor 1)'s role as the principal thrombin receptor or modeling its functions in platelet aggregation and emerging roles in neural biology. The Knockout line is the standard tool for asking whether PAR1 is required for thrombin-induced signaling — F2R/PAR1 is the primary thrombin receptor activated by thrombin cleavage of the extracellular N-terminus (LDPR41/S42), exposing a tethered ligand (SFLLRN) that activates Gαq, Gα12/13, and Gi signaling; PAR1 is critical for platelet aggregation downstream of thrombin in hemostasis. Overexpression is useful for studying PAR1 gain-of-function effects. For neural research, the EDITGENE F2R Knockout in SK-N-SH is relevant — SK-N-SH is a neuroblastoma cell line, and PAR1 has been characterized as expressed in neural cells with emerging roles in neuroinflammation and neuroprotection following thrombin exposure (BBB disruption, hemorrhage). Rescue with wild-type or cleavage-resistant PAR1 (R41A) enables structure-function studies. The knockout is a critical specificity control for ⭐ vorapaxar (Zontivity, FDA-approved 2014 antiplatelet PAR1 antagonist for cardiovascular events post-MI), atopaxar, and emerging PAR1-targeted therapeutics.

Yes. PAR1 rescue experiments require attention to thrombin cleavage activation: • Construct design: use a codon-modified F2R sequence with a small intracellular C-terminal tag (FLAG, HA). PAR1 is a seven-transmembrane GPCR — preserve N-terminal extracellular tail with thrombin cleavage site (LDPR41/S42). • Cleavage-resistant rescue: R41A mutation in the thrombin cleavage site abolishes thrombin activation while preserving PAR1-AP (SFLLRN) responsiveness — enabling separation of biased activation modes. • Surface localization validation: confirm plasma membrane localization before functional assays. • Vorapaxar resistance studies: PAR1 mutations conferring vorapaxar resistance for on-target inhibitor validation. • Functional readout: rescue should restore thrombin-induced phospho-ERK and Ca²⁺ mobilization. SK-N-SH-specific considerations: • SK-N-SH is a human neuroblastoma cell line (parental line to the more widely used SH-SY5Y subclone) — used for neuronal biology and neuroblastoma research. • Lentiviral transduction is supported with moderate efficiency. • SK-N-SH exhibits both N-type (neuronal) and S-type (epithelial-like) morphology that can affect phenotypic analysis — characterize cellular subtype before phenotypic assays.

Important nomenclature clarification: FLVCR2 (feline leukaemia virus subgroup C cellular receptor family member 2, MFSD7C, SLC49A2) was historically annotated as a heme transporter based on its sequence relationship to FLVCR1 and its identification as the feline FeLV-C receptor. However, recent breakthrough studies (Nguyen et al. Cell Research 2024; Nature 2024 structural studies) have established that the principal physiological substrate of human FLVCR2 is choline, not heme — FLVCR2 functions as a blood-brain barrier choline transporter responsible for approximately 60% of choline uptake into the brain. The choice between knockout and overexpression depends on whether you are studying FLVCR2 as a choline transporter or modeling Fowler syndrome. The Knockout line is the standard tool for asking whether FLVCR2 is required for choline transport or for FLVCR2-dependent processes. For BBB and choline transport research, the EDITGENE FLVCR2 Knockout in Huh-7 enables study of FLVCR2 biology — though physiological BBB choline transport requires brain microvascular endothelial cell models. Biallelic FLVCR2 loss-of-function mutations cause Fowler syndrome (proliferative vasculopathy and hydranencephaly-hydrocephaly, PVHH; OMIM 225790) — embryonic lethal cerebral vascular disease. Rescue with wild-type or transport-deficient FLVCR2 enables structure-function studies. The knockout is valuable for studying recently characterized FLVCR2 choline transport biology, Fowler syndrome mechanisms, and emerging brain choline delivery therapeutic strategies.

Yes. FLVCR2 rescue experiments require attention to MFS transporter architecture and the recently characterized choline transport function: • Construct design: use a codon-modified FLVCR2 sequence with a small intracellular tag (FLAG, HA). FLVCR2 has 12 transmembrane domains characteristic of MFS transporters — preserve membrane topology. • Surface localization validation: confirm plasma membrane localization by cell surface staining before choline transport assays. • Transport-deficient rescue: substrate-binding pocket mutations (e.g., aromatic and polar residues in the central choline-binding cavity, recently characterized by cryo-EM 2024) abolish choline transport and serve as the standard specificity control. • Fowler syndrome mutation rescue: patient-derived FLVCR2 mutations enable disease genotype-function studies. • Functional readout: rescue should restore choline uptake measured by ¹⁴C-choline or fluorescent choline analog cellular uptake. Huh-7 transduces efficiently with lentivirus and supports stable rescue line generation.

The choice depends on whether you are studying FTO (fat mass and obesity-associated)'s role as the principal m6A (N6-methyladenosine) RNA demethylase or modeling its functions in bovine mammary epithelial biology and lactation. The Knockout line is the standard tool for asking whether FTO is required for these processes — FTO is a 2OG/Fe(II)-dependent dioxygenase that removes m6A modifications from mRNA (and m1A from tRNA, m6Am from cap structures), making it one of two principal m6A 'erasers' (with ALKBH5); FTO common variants are the strongest genetic association with obesity in human GWAS (T allele of rs9939609 is in FTO intron 1 and increases obesity risk). Overexpression is useful for studying FTO in heterologous expression contexts. For bovine lactation and m6A epitranscriptomics research, the EDITGENE FTO Knockout in MAC-T is uniquely valuable — MAC-T is a SV40-immortalized bovine mammary alveolar epithelial cell line, providing a physiologically relevant context for studying FTO biology in milk-producing cells with implications for dairy production. Rescue with wild-type or catalytically-dead FTO is the standard specificity control. The knockout is valuable for studying m6A epitranscriptomics in lactation biology, dairy productivity genetics, and emerging FTO-targeted approaches in obesity drug development (FTO inhibitors like FB23-2, meclofenamic acid have been explored).

Yes. FTO rescue experiments require attention to dioxygenase architecture: • Construct design: use a codon-modified FTO sequence with a small C-terminal tag (FLAG, HA). FTO has N-terminal AlkB-like dioxygenase domain and C-terminal β-helix domain — preserve all elements. • Catalytically-dead rescue: H231A or D233A active site Fe(II)-coordinating residue mutations abolish demethylase activity and serve as the standard specificity control. • Cross-species considerations: the rescue cDNA should be species-matched (bovine FTO) for physiological relevance in MAC-T context; human FTO can also rescue given evolutionary conservation. • Functional readout: rescue should restore m6A demethylase activity measured by global mRNA m6A levels (LC-MS) or m6A-RIP-seq analysis of specific mRNAs. MAC-T-specific considerations: • MAC-T is a SV40-immortalized bovine mammary alveolar epithelial cell line (also designated as MAC-T cells with myoepithelial/ductal-like profile) — the principal continuous bovine mammary cell model for lactation, milk protein production, and dairy/agricultural research. • Lentiviral transduction efficiency in MAC-T cells may require optimization; the bovine species background must be considered for ortholog and antibody cross-reactivity. • MAC-T cells constitutively express β-casein and respond to lactogenic hormones (prolactin, growth hormone) — these features can be exploited for studying mammary epithelial function in the FTO-null context.

The choice depends on whether you are studying FIG4 (factor-induced gene 4, SAC3)'s role as a PI(3,5)P2 5-phosphatase or modeling Charcot-Marie-Tooth disease type 4J (CMT4J), Yunis-Varón syndrome, and amyotrophic lateral sclerosis. The Knockout line is the standard tool for asking whether FIG4 is required for these processes — FIG4 is a phosphoinositide phosphatase that dephosphorylates PI(3,5)P2 to PI(3)P; paradoxically, FIG4 loss reduces (rather than increases) PI(3,5)P2 levels because FIG4 also positively regulates the PI(3,5)P2-synthesizing kinase PIKfyve via scaffolding within the PAS complex (PIKfyve, FIG4, VAC14). Overexpression is useful for studying FIG4 gain-of-function effects. For lysosomal biology research, the EDITGENE FIG4 Knockout in HAP1 enables study of PI(3,5)P2 biology and PIKfyve pathway. FIG4 biallelic loss-of-function mutations cause Charcot-Marie-Tooth disease type 4J (autosomal recessive peripheral neuropathy) and Yunis-Varón syndrome; FIG4 has been characterized as an ALS risk gene. Rescue with wild-type or phosphatase-dead FIG4 enables structure-function studies. The knockout is valuable for studying endolysosomal biology, autophagy, and PIKfyve inhibitor (apilimod) specificity.

Yes. FIG4 rescue experiments require attention to PAS complex scaffolding: • Construct design: use a codon-modified FIG4 sequence with a small C-terminal tag (FLAG, HA). FIG4 has SAC domain phosphatase region and C-terminal VAC14-interaction region — preserve all elements. • Phosphatase-dead rescue: SAC domain catalytic residue mutations abolish phosphatase activity but retain scaffolding function — invaluable for separating catalytic from scaffolding roles. • VAC14-binding-deficient rescue: C-terminal mutations disrupt PAS complex assembly. • CMT4J mutation rescue: patient-derived FIG4 mutations (I41T common in CMT4J, others) enable disease genotype-function studies. • Functional readout: rescue should restore endolysosomal morphology (no enlarged vacuoles) and PI(3,5)P2 levels. HAP1-specific considerations: • Diploidization: HAP1 cells gradually diploidize during extended culture — confirm ploidy by flow cytometry at the time of phenotypic assay. • Integration site sensitivity: position effects on transgene expression are more pronounced in near-haploid backgrounds; generating multiple independent rescue clones is strongly recommended. • Transduction efficiency: HAP1 transduces with lentivirus at moderate efficiency — increase MOI compared to standard immortalized lines.

The choice depends on whether you are studying CXCR4 (C-X-C chemokine receptor 4, CD184)'s role as the principal CXCL12/SDF-1 receptor or modeling its functions in HIV entry, stem cell mobilization, and WHIM syndrome. The Knockout line is the standard tool for asking whether CXCR4 is required for these processes — CXCR4 is a Gαi-coupled seven-transmembrane GPCR activated by CXCL12/SDF-1α, with established roles in hematopoietic stem cell retention in bone marrow, T-lymphocyte trafficking, and cancer metastasis; CXCR4 is also a co-receptor for X4-tropic HIV entry. Overexpression is useful for studying CXCR4 gain-of-function effects. For HIV, stem cell, and cancer metastasis research, the EDITGENE CXCR4 Knockout in HEK293T is a workhorse mechanistic platform — HEK293T's very high transfection efficiency supports systematic structure-function studies. Rescue with wild-type, signaling-deficient, or WHIM-associated truncation mutant (e.g., R334X — WHIM syndrome causes gain-of-function CXCR4 truncations that resist β-arrestin-mediated internalization) CXCR4 enables comprehensive disease and pharmacology studies. The knockout is a critical specificity tool for ⭐ plerixafor (Mozobil, FDA-approved CXCR4 antagonist for HSC mobilization in lymphoma/myeloma transplants), mavorixafor (Xolremdi, FDA-approved 2024 for WHIM syndrome), motixafortide, and emerging CXCR4-targeted therapies.

Yes. CXCR4 rescue experiments are well-established for chemokine receptor research: • Construct design: use a codon-modified CXCR4 sequence with a small intracellular C-terminal tag (FLAG, HA). CXCR4 is a seven-transmembrane GPCR with extracellular CXCL12-binding pocket — preserve all elements; note that C-terminal tags may affect β-arrestin recruitment. • Surface localization validation: confirm plasma membrane localization before CXCL12 binding studies. • Signaling-deficient rescue: DRY motif mutations disrupt Gαi-coupling. • WHIM mutation rescue: R334X and other C-terminal truncation mutations cause WHIM syndrome by resisting β-arrestin-mediated internalization, generating gain-of-function CXCR4 — invaluable for disease modeling. • HIV co-receptor studies: HIV envelope-mediated entry assays following CXCR4 rescue. • Functional readout: rescue should restore CXCL12-induced Gαi signaling, β-arrestin recruitment, and receptor internalization. HEK293T transduces with very high efficiency and supports stable rescue line generation for systematic CXCR4 mutation analysis.